scholarly journals Hypotension in pregnant women: a population-based case–control study of pregnancy complications and birth outcomes

2010 ◽  
Vol 34 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Ferenc Bánhidy ◽  
Nándor Ács ◽  
Erzsébet H Puhó ◽  
Andrew E Czeizel
Keyword(s):  
Pregnant Women ◽  
Birth Outcomes ◽  
Pregnancy Complications ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Control Study

scholarly journals Birth outcomes and pregnancy complications of women with uterine leiomyoma—a population-based case-control study

Health ◽  
2010 ◽  
Vol 02 (06) ◽  
pp. 566-574
Author(s):  
Ferenc Bánhidy ◽  
Nándor ács ◽  
Erzsébet H. Puhó ◽  
Andrew E. Czeizel
Keyword(s):  
Birth Outcomes ◽  
Pregnancy Complications ◽  
Uterine Leiomyoma ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Control Study

scholarly journals Population-based case-control study of mebendazole in pregnant women for birth outcomes

2005 ◽  
Vol 45 (3) ◽  
pp. 85-88 ◽  
Author(s):  
Nandor Acs ◽  
Ferenc Banhidy ◽  
Erzsebet Puho ◽  
Andrew E. Czeizel
Keyword(s):  
Pregnant Women ◽  
Birth Outcomes ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Control Study

Maternal-Fetal Management in Trombophilia Related and Placenta-Mediated Pregnancy Complications

2018 ◽  
Vol 69 (9) ◽  
pp. 2396-2401
Author(s):  
Costin Berceanu ◽  
Elena Loredana Ciurea ◽  
Monica Mihaela Cirstoiu ◽  
Sabina Berceanu ◽  
Anca Maria Ofiteru ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Pregnancy Complications ◽  
Case Control Study ◽  
Case Control ◽  
Placental Insufficiency ◽  
Management Options ◽  
Specific Therapy ◽  
Pregnancy Morbidity ◽  
The Impact ◽  
Control Study

It is widely accepted that thrombophilia in pregnancy greatly increases the risk of venous thromboembolism. Pregnancy complications arise, at least partly, from placental insufficiency. Any change in the functioning of the gestational transient biological system, such as inherited or acquired thrombophilia, might lead to placental insufficiency. In this research we included 64 pregnant women with trombophilia and 70 cases non-trombophilic pregnant women, with or without PMPC, over a two-year period. The purpose of this multicenter case-control study is to analyze the maternal-fetal management options in obstetric thrombophilia, the impact of this pathology on the placental structure and possible correlations with placenta-mediated pregnancy complications. Maternal-fetal management in obstetric thrombophilia means preconceptional or early diagnosis, prevention of pregnancy morbidity, specific therapy as quickly as possible and fetal systematic surveilance to identify the possible occurrence of placenta-mediated pregnancy complications.

scholarly journals Birth outcomes of cases with right sided obstructive defects of heart – a population-based case-control study

2013 ◽  
Vol 1 (1) ◽  
Author(s):  
Attila Vereczkey ◽  
Zsolt Kósa ◽  
Melinda Csáky-Szunyogh ◽  
Róbert Urbán ◽  
Andrew E Czeizel
Keyword(s):  
Birth Outcomes ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Control Study

Are Anti-β2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Case–Control Study

2018 ◽  
Vol 35 (11) ◽  
pp. 1093-1099 ◽  
Author(s):  
Leslie Skeith ◽  
Karim Abou-Nassar ◽  
Mark Walker ◽  
Tim Ramsay ◽  
Ronald Booth ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Pregnancy Complications ◽  
Case Control Study ◽  
Late Pregnancy ◽  
Case Control ◽  
Immunoglobulin M ◽  
Enzyme Linked Immunosorbent Assay ◽  
Significant Difference ◽  
Antibody Positivity ◽  
Control Study

Background While anti-β2 glycoprotein 1 (anti-β2GP1) antibody positivity is included in the diagnostic criteria for antiphospholipid syndrome (APS), the association between anti-β2GP1 and the obstetrical complications of APS has been inconsistently reported and remains unclear. Objective We completed a case–control study nested within the Canadian Ottawa and Kingston (OaK) Birth Cohort to evaluate the association between anti-β2GP1 antibody positivity and placenta-mediated pregnancy complications. Study Design Five hundred cases were randomly selected among pregnant women who experienced any of the following independently adjudicated placenta-mediated pregnancy complications: preeclampsia, placental abruption, late pregnancy loss (≥ 12 weeks' gestation), and birth of a small-for-gestational age (SGA) infant < 10th percentile. Five hundred pregnant women without any placenta-mediated pregnancy complications were selected as controls. Stored blood samples were analyzed for the presence of anti-β2GP1 antibodies by enzyme-linked immunosorbent assay. Results Anti-β2GP1 immunoglobulin G (IgG) and/or immunoglobulin M (IgM) antibodies in titers ≥ 20 G/M units (> 99th percentile) were present in 24 of 497 (4.8%) of controls and 33 of 503 (6.6%) of cases. There was no significant difference between cases and controls for the composite outcome of any placenta-mediated pregnancy complications (odds ratio, 1.38, 95% confidence interval [CI], 0.8–2.37, p = 0.25). Conclusion Our results call into question the association between anti-β2GP1 antibodies and placenta-mediated pregnancy complications, with further research needed.

Sign in / Sign up

Export Citation Format

Share Document